CN103393704B - Houttuynoid E在制备治疗动脉粥样硬化药物中的应用 - Google Patents
Houttuynoid E在制备治疗动脉粥样硬化药物中的应用 Download PDFInfo
- Publication number
- CN103393704B CN103393704B CN201310261342.4A CN201310261342A CN103393704B CN 103393704 B CN103393704 B CN 103393704B CN 201310261342 A CN201310261342 A CN 201310261342A CN 103393704 B CN103393704 B CN 103393704B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- group
- atherosclerosis
- medicine
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- VCNWTZPWIVDHGN-SLBJRTIWSA-N 2-[4,5-dihydroxy-2-(2-oxoundecyl)phenyl]-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound CCCCCCCCCC(=O)CC1=CC(O)=C(O)C=C1C1=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 VCNWTZPWIVDHGN-SLBJRTIWSA-N 0.000 title abstract description 78
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 229930190556 houttuynoid Natural products 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 210000003725 endotheliocyte Anatomy 0.000 abstract description 7
- 230000000879 anti-atherosclerotic effect Effects 0.000 abstract description 5
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 5
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000000489 anti-atherogenic effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 12
- 241000700159 Rattus Species 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 3
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310261342.4A CN103393704B (zh) | 2013-06-24 | 2013-06-24 | Houttuynoid E在制备治疗动脉粥样硬化药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310261342.4A CN103393704B (zh) | 2013-06-24 | 2013-06-24 | Houttuynoid E在制备治疗动脉粥样硬化药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103393704A CN103393704A (zh) | 2013-11-20 |
CN103393704B true CN103393704B (zh) | 2015-08-19 |
Family
ID=49557559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310261342.4A Active CN103393704B (zh) | 2013-06-24 | 2013-06-24 | Houttuynoid E在制备治疗动脉粥样硬化药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103393704B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721366A (en) * | 1993-03-31 | 1998-02-24 | G. D. Searle & Co | Platelet aggregation inhibitors |
-
2013
- 2013-06-24 CN CN201310261342.4A patent/CN103393704B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103393704A (zh) | 2013-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080081081A1 (en) | Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity | |
CN103222988A (zh) | 一种美洲大蠊提取物及其制备方法和应用 | |
CN102552644A (zh) | 大蒜总多糖的抗癌用途、制备方法及组合物 | |
WO2015190872A1 (ko) | 스피루리나 추출물을 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물 | |
CN103356604B (zh) | Chukrasone B在制备治疗动脉粥样硬化药物中的应用 | |
CN101264069A (zh) | 白藜芦醇的衍生物在制备治疗与免疫相关疾病药物中的应用 | |
CN102861037B (zh) | Gypensapogenin B在治疗动脉粥样硬化药物中的应用 | |
CN103393704B (zh) | Houttuynoid E在制备治疗动脉粥样硬化药物中的应用 | |
CN103381188B (zh) | Houttuynoid B在制备治疗动脉粥样硬化药物中的应用 | |
CN105287450A (zh) | Nootkatone在制备治疗动脉粥样硬化药物中的应用 | |
CN103381176B (zh) | Houttuynoid C在制备治疗动脉粥样硬化药物中的应用 | |
Wang et al. | Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum | |
CN105380944A (zh) | Volvalerelactones A在制备治疗动脉粥样硬化药物中的应用 | |
CN109260214A (zh) | 芍药苷类化合物在制备治疗脓毒症药物中的应用 | |
CN103356667A (zh) | Houttuynoid A在治疗动脉粥样硬化药物中的应用 | |
CN103393641A (zh) | Sarcaboside A在治疗动脉粥样硬化药物中的应用 | |
CN103027908A (zh) | Aphanamixoid A在制备治疗动脉粥样硬化药物中的应用 | |
CN103356685A (zh) | Houttuynoid D在治疗动脉粥样硬化药物中的应用 | |
CN103372017A (zh) | Chukrasone A在制备治疗动脉粥样硬化药物中的应用 | |
CN103356632A (zh) | Aspeverin在制备治疗动脉粥样硬化药物中的应用 | |
CN103356587A (zh) | Sarcaboside B在治疗动脉粥样硬化药物中的应用 | |
CN103120675A (zh) | Eryngiolide A在治疗动脉粥样硬化药物中的应用 | |
CN106491590A (zh) | Linderolide H在制备治疗动脉粥样硬化药物中的应用 | |
CN103251645A (zh) | Polyflavanostilbene A在制备治疗动脉粥样硬化药物中的应用 | |
CN100409863C (zh) | 双黄连在制备治疗动脉粥样硬化药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171116 Address after: 401120 Chongqing Yubei District Food City Avenue 18 Chongqing advertising industrial park office space Patentee after: Chongqing San Mou science and Technology Development Co., Ltd. Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Patentee before: Ding Shengyu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201228 Address after: 224200 No.88 Gangcheng Avenue, Dongtai coastal economic zone, Yancheng City, Jiangsu Province Patentee after: Dongtai Haibin science and Technology Pioneer Park Management Co., Ltd Address before: 401120 office building of Chongqing advertising industrial park, No.18, shifucheng Avenue, Yubei District, Chongqing Patentee before: CHONGQING SUMARTE TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right |